Creative Biolabs is a contract research organization (CRO) specialized in offering customized services for the development of antibodies for use in diagnostics, drug discovery, and basic research. Especially, we provide the expertise and personnel to offer high-quality in vitro diagnostic (IVD) antibody development services targeting a wide range of high-value diagnostic biomarkers to our clients. Here, we introduce our IVD antibody development services for ECP marker.
Eosinophil Cationic Protein (ECP)
Eosinophil cationic protein (ECP), a basic protein located in the eosinophil primary matrix, is encoded in humans by the RNASE3 gene. ECP is released during degranulation of eosinophils. This protein is related to inflammation and asthma because in these cases, there are increased levels of ECP in the body. There are three glycosylated forms of ECP, so the molecular weight of ECP ranges from 18-22 kDa.
Eosinophil granulocytes appear in large numbers in inflammation sites and in response to certain parasitic infections. These cytoplasmic granulocytes contain positively charged proteins that characterize the cells. ECP is one of the four highly basic proteins that enter the surrounding tissues when activated eosinophils degranulate. Although circulating ECP levels can vary widely among patients, some studies show that serum ECP measurements are useful in monitoring many active inflammatory diseases. During the inflammatory response marked by activated eosinophils, ECP concentrations in plasma and other body fluids increase.
Fig.1 Effects of the eosinophil cationic protein (ECP). (Koczera, P. 2016)
ECP Marker of Asthma
There is now a good body of evidence that ECP can be used to assess asthma severity and it has been widely investigated as a potential biomarker of airway inflammation. As a direct marker of eosinophilic inflammation of the bronchi, ECP is helpful in asymptomatic asthmatic patients.
There is strong evidence that sputum ECP is raised in asthmatics, both in children and adults, and is increased in classic asthma, cough-variant asthma, and occupational asthma. Serum ECP levels are a useful objective measurement of asthma severity as an increase in ECP level corresponds to the onset of symptoms. In seasonal asthmatic patients, ECP measurement reflected changes in disease activity throughout the year. Serum ECP measurement for assessing asthma severity, monitoring therapy, and indicating severity of certain inflammatory skin conditions present an advantage over subjective clinical measures that are prone to inconsistencies due to broad variability of individual investigator and patient assessments, especially in young children. The normal reference range for blood tests for eosinophil cationic protein is between 2.3 and 16 µg/L.
IVD Antibody Development Services Targeting ECP Marker
Based on the rapid development of IVD technology and novel biomarkers, IVD antibodies are extensively used for disease screening and therapeutic monitoring. Diverse immunoassays are applied, including lateral flow assay, immunochemistry, sandwich ELISA, etc. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to deliver high-quality IVD antibody development services targeting numerous biomarkers, such as the ECP marker.
With years of devotion and accumulation in this particular field, Creative Biolabs is confident in offering you the best products and services. For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
For Research Use Only.
